Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $300.1 million. The offering is expected to close on or about August 16, 2024, subject to the satisfaction of customary closing conditions.
Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the development of its clinical programs, to advance research and development associated with its AOC platform and for working capital and general corporate purposes.
在扣除承销折扣和佣金以及其他发行费用之前，预期Avidity将从此次发行中获得的总收益约为300.10万美元。预计该发行将于2024年8月16日左右结束，视符合惯常的结算条件而定。
Avidity计划将本次发行的净收益与其现有现金、现金等价物和可流通证券资金一起，用于资助其临床项目的开发、推进与AOC平台相关的研究和开发以及用于营运资金和一般企业用途。